← Back to guidelines
Oncology11 papers

Metastatic carcinoma to nasopharynx

Last edited: 4/10/2026

Overview

Metastatic carcinoma to the nasopharynx, also known as nasopharyngeal carcinoma (NPC), is a malignancy originating in the nasopharyngeal epithelium. Treatment strategies are often guided by the stage of the disease, with definitive-intent chemoradiotherapy being a key approach for locally advanced stages.

Diagnosis

  • Diagnosis is typically based on clinical presentation, imaging (e.g., MRI, CT, PET-CT), and histopathological confirmation via biopsy 1.
  • Management

  • Definitive-intent chemoradiotherapy is recommended for stage II-IVA nasopharyngeal carcinoma 1.
  • Treatment considerations include the sequence of chemotherapy and radiotherapy, as well as the use of concurrent, induction, or adjuvant chemotherapy 1.
  • Key Recommendations

  • Chemotherapy in combination with radiotherapy is recommended for the definitive-intent treatment of stage II to IVA nasopharyngeal carcinoma 1. (Evidence: Strong)
  • Evidence-based recommendations address aspects of care related to chemotherapy in combination with RT for the definitive-intent treatment of stage II to IVA NPC, including radiotherapy, chemotherapy sequence, and concurrent, induction, and adjuvant chemotherapy options 1. (Evidence: Strong)
  • References

    1 Chen YP, Ismaila N, Chua MLK, Colevas AD, Haddad R, Huang SH et al.. Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021. link

    Original source

    1. [1]
      Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline.Chen YP, Ismaila N, Chua MLK, Colevas AD, Haddad R, Huang SH et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG